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Annealed and non-annealed freeze-dried wafers from synthesised thiolated-chitosan have been 
developed and evaluated. Wafers were obtained by freeze-drying aqueous gels of the thiolated 
polymer incorporating per polymer weight, 10 % each of glycerol as plasticizer, D-mannitol as 
cryoprotectant and 50% BSA as model protein drug. The formulation was freeze-dried with or 
without the process of annealing. Texture analyzer was employed to investigate the in vitro mu-
coadhesive properties in tensile mode, residual moisture content by thermo-gravimetric analysis 
(TGA) while hydration capacity and drug release studies were performed in 0.1M PBS. Micro-
scopic architecture was examined using scanning electron microscopy (SEM). Differential scan-
ning calorimetry (DSC) was employed for protein phase separation studies and conformational 
stability by attenuated total reflectance-Fourier tansform infra-red spectroscopy (ATR-FTIR) 
and confirmed with Circular dichroism (CD). The annealing process led to wafers with in-
creased ease of hydration, improved in vitro mucoadhesive characteristics and enhanced BSA 
release, without affecting the conformational stability of the protein due to the presence of a 
cryoprotectant. These results show the potential application of annealed freeze-dried thiolated-
chitosan wafers for buccal mucosa delivery of protein based drugs.  
INTRODUCTION  
Chitosan (CS) (poly[-(1,4)-2-amino-2-deoxy-D
-glucopiranose])  is a natural polymer obtained 
by deacetylation of chitin (Wu et al., 2009). 
Due to its biocompatibility and biodegradation 
properties (VandeVord et al., 2002), chitosan 
has been used primarily for the purpose of im-
proved mucoadhesion, permeation enhance-
ment and drug delivery (Agnihotri et al., 2004) 
via mucosal routes such as GI mucosa (Van 
Der Lubben et al., 2001; Read et al., 2005), 
buccal (Giunchedi et al., 2002), and ocular (De 
Campos et al., 2004).  
The mucoadhesive properties exhibited by chi-
tosan have been further improved by derivatiza-
tion to generate thiolated-chitosans. Factors that 
can alter the interaction between the polymer 
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 tine was purchased from Fischer Scientific 
(Loughborough, UK). All other reagents were 
of analytical grade and were used without fur-
ther purification.  
 
Chitosan-4-thioglycolic acid (CS-TGA) syn-
thesis and purification   
Synthesis of CS-TGA was by method previ-
ously described (Saboktakin et al., 2011). 500 
mg of CS was dissolved in 50 mL of 0.1 M 
HCl. An equivalent of 500 mg of thioglycolic 
acid (TGA) was added followed by 50 mM 
EDAC in order to activate the carboxylic acid 
moieties of TGA, the pH adjusted to 5 with 1M 
NaOH at room temperature and stirred for 3 
hours. Purification to remove unconjugated 
TGA and sulfhydryl immobilization determina-
tion of CS-TGA was by the method reported in 
literature (Bernkop-Schnurch et al., 2004), us-
ing Float-A-Lyzer G2 dialysis device (8-10 
kDa Molecular weight cut-off, Sigma Gilling-
ham, UK) and Ellman’s reaction with standard 
cysteine HCl curve (r2 > 0.99) respectively. 
 
Gel formulation and freeze-drying 
Ten percent (per polymer weight) each of glyc-
erol and D-mannitol as plasticizer and cryopro-
tectant respectively were added to the recov-
ered dialysed gel and loaded with BSA as a 
model protein drug in a 2:1 CS-TGA: BSA 
ratio. The final formulated gel was stirred con-
tinuously for 30 minutes at room temperature to 
obtain a uniform gel which was kept under am-
bient conditions to remove all air bubbles.   
 
Six grammes (6.0g) of the homogeneous gel 
was transferred into a mould (diameter 35mm) 
and freeze-dried using a novel freeze-drying 
cycle developed with differential scanning 
calorimetry (DSC) (Ayensu et al., 2011) on a 
Virtis AdVantage XL 70 freeze dryer 
(Biopharma Process Systems, Winchester, 
UK). An annealing temperature of -25°C (3 
hours) was applied during the freezing phase (-
55°C). Primary and secondary drying were at -
30°C and 20°C respectively, with a vacuum of 
20 mtorr for 34 hours. The effect of annealing 
on the physico-mechanical properties of the 
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and the mucosal layer can affect the mucoadhe-
sive property. These include polymer molecular 
weight (Andrew et al., 2009), polymer concen-
tration (Solomonidou et al., 2001) and drying 
method. Freeze-dried formulations offer stable 
products, extend shelf-life and allows storage 
of products at room temperature (Bunte et al., 
2010). However, during the freezing stage of 
freeze-drying, low molecular weight compo-
nents tend to undergo incomplete crystalliza-
tion resulting in the formation of mixtures of 
different polymorphs (Liao et al., 2007). Such 
processes may cause reproducibility and prod-
uct characterization problems. Annealing may 
be employed to foster crystallization of the in-
gredients and to improve pore size of ice crys-
tals (Searles et al., 2001a).  
 
This report describes the development and 
evaluation of the functional characteristics of 
freeze-dried annealed and non-annealed 
thiolated-chitosan wafers, as potential drug 
delivery systems via the buccal mucosa. The 
wafers were characterised for moisture content, 
mucoadhesion properties and microscopic 
structure using thermo-gravimetric analysis 
(TGA), texture analysis (TA) and scanning 
electron microscopy (SEM) respectively. The 
conformational stability of bovine serum albu-
min (BSA) was studied with attenuated total 
reflectance–Fourier transform infra-red spec-
troscopy (ATR-FTIR) and circular dichroism 
(CD). The effect of annealing on hydration, 
mucoadhesion and the release of BSA from the 
formulations were also evaluated. 
 
MATERIALS AND METHODS 
Materials 
Chitosan (medium molecular weight, 190-310 
kDa, 75-85 % deacetylated), BSA (mol wt ~ 
66 kDa), glycerol, D-mannitol, Bradford re-
agent, thioglycolic acid (TGA), N-(3-
dimethylaminopropyl)-N-ethyl carbodiimide 
hydrochloride (EDAC), L-cysteine hydrochlo-
ride, 5,5′-dithiobis (2-nitrobenzoic acid) 
(Ellman’s reagent) and mucin (from bovine 
submaxillary gland, Type I-S) were all obtained 
from Sigma (Gillingham, UK). Pulverised gela-
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drug loaded formulations was determined by 
freeze-drying with or without the process of 
annealing. Resultant freeze-dried wafers were 
stored over anhydrous silica gel till ready for 
characterisation. 
 
Physico-mechanical characterisation of 
wafers 
SEM 
The external surfaces of the freeze-dried wafers 
were placed on the exposed side of a double 
sided carbon adhesive tape on labelled stainless 
steel stubbs and sputter coated with gold for 
120 seconds at 1 kV and 30mA (Edwards Sput-
ter Coater S150B). They were then placed in 
the chamber of a Cambridge Stereoscan S-360 
SEM (Class one equipment, London UK). Im-
ages were processed with i-scan2000 software 
after acquisition at an accelerating voltage of 
20KV and a working distance of 15 mm.  
 
Swelling capacity 
The wafers were initially weighed and the 
swelling behaviour observed at predetermined 
time intervals (Wu et al., 2009) by incubation 
at 37 ± 0.1°C in 25mL of 0.1M PBS solution 
(pH 6.8 ± 0.1 simulating salivary pH). The 
samples were removed and blotted off carefully 
between tissue papers to remove the surface-
adhered liquid droplets and reweighed on an 
electronic balance to a constant weight. The 
percentage of water uptake was calculated as 
follows: 
 
Swelling capacity (%) = 100 x (Pi –P) /P..          (1)                                               
 
where Pi is the weight of the hydrated wafer, 
and  P is the initial weight of wafer. 
 
Moisture content  
The estimation of percentage residual moisture 
of the freeze-dried wafers was by Thermal 
Advantage TGA 2950 (TA Instruments, 
Crawley UK) (Wang, W. 2000). Wafers 
weighing between 3 – 6mg were placed in a 
previously tared 70µl aluminium crucible and  
a constant phase of heating at 15°C/min from 
ambient temperature to a maximum of 150 °C 
was applied with a constant stream of dry 
nitrogen. The percentage weight loss from a 
second derivative plot was determined using 
TA Universal Analysis 2000 programme.  
 
In vitro mucoadhesion studies 
Mucoadhesive measurements were performed 
on the freeze-dried annealed and non-annealed 
CS-TGA-BSA wafers using our previously 
reported method (Ayensu et al. 2011). Briefly, 
samples (n = 4) were attached to a 75mm di-
ameter adhesive rig probe with a double sided 
adhesive tape on a TA.HD.plus Texture Ana-
lyser (Stable Micro Systems, Surrey, UK) fitted 
with a 5kg load cell in tension mode. A set 
gelatine gel in a Petri-dish (diameter 88mm) 
was used to represent the buccal mucosal sur-
face for the in vitro measurement. The model 
mucosal substrate was equilibrated with 2% 
mucin solution (adjusted to pH of 6.8 ± 0.1) for 
60 seconds and placed on the instrument plat-
form. The probe, lined with wafer was set to 
approach the model mucosal surface with pre-
test speed of 0.5mm/s, test speed of 0.5mm/s 
and post speed of 1.00mm/s. The Texture Ex-
ponent 32 software was employed to record and 
process the data. The maximum force required 
to detach the wafer on the upper probe from the 
mucosal surface, known as the peak adhesive 
(PAF) was determined. The area under the 
curve (AUC) representing total work of adhe-
sion (TWA) of the wafers was estimated from 
the force-distance plot whiles the cohesiveness 
of the samples was determined by the distance 
of travel. The influence of annealing on muco-
adhesive strength of the thiolated wafers was 
investigated. 
 
In vitro BSA release profiles 
The freeze-dried wafers were immersed in 
beakers containing 50ml of 0.1M PBS (pH 6.8 
± 0.1) solution as release medium at 37 ± 0.1 °
C, covered (Nochos et al., 2008) and stirred at 
150rpm with a magnetic stirrer. Fifty µL of 
each sample was withdrawn at predetermined 
time intervals, replaced with the same amount 
of the release medium to maintain a constant 
volume for 7 hours and treated with 1mL Brad-
Lyophilized thiolated-chitosan wafers ... 48 





ford’s reagent and the absorbance measured at 
595nm and 450nm (Ernst and Zor, 2010). A 
linearised calibration curve (r2 > 0.99) was 
used to determine the concentration of the BSA 
released and the corresponding cumulative per-
centage drug release profiles of BSA were then 
plotted. 
 
Stability of protein in freeze-dried wafers 
DSC 
The freeze-dried CS-TGA wafers were studied 
for possible phase separation after freeze-
drying on the DSC. This involved the initial 
cooling on the DSC at 10 °C/min from 25 to - 
50 °C. It was then heated at a rate of 20 °C /min 
to 200 °C and the cycle repeated. An empty 
aluminium pan was used as reference. Mettler 
STARe software was used to analyse and 
evaluate the DSC thermograms.  
 
ATR- FTIR analysis 
ATR-FTIR spectra of the samples were 
acquired on an Excalibur series FTS 3500 ARX 
FTIR, equipped with Specac Golden gate 
(Varian, Oxford UK). Win IR PRO software of 
wave number range 600 – 4000 cm−1 was used 
for the analysis. The spectra were collected at a 
resolution of 1.5 cm−1 with 16 scans per 
spectrum. A background spectrum was 
acquired and assigned for use on subsequent 
spectral acquisitions for each sample. 
 
Conformational stability of BSA- CD 
The secondary structure of BSA in the freeze-
dried wafers was examined using far-UV CD. 
Spectrum of a 0.5mg/mL solution of native 
BSA dissolved in 0.1M PBS (pH 6.8) as the 
negative control or BSA released from the 
freeze-dried wafers was recorded at 25 °C from  
wavelength range 240 ≥ λ ≥ 190 with band-
width 1nm, time-per-point 0.5 s, and  cell path-
length of 0.1 mm using CD spectroscopy 
(Chirascan, Applied Photophysis, Surrey, UK) . 
The mean residue ellipticity [θ] mrw, k was 
determined by:  
 
          
where θk is the observed ellipticity (degrees) at 
wavelength k, d is the pathlength (cm), and c is 
the concentration (g/mL) (Kelly et al., 2005).  
 
Statistical evaluation 
Statistical evaluation of data was carried out 
using two tailed student t-test with 95 % confi-
dence interval as the minimal level of signifi-
cance. 
 
RESULTS AND DISCUSSION 
Chitosan-4-thioglycolic acid (CS-TGA) syn-
thesis and purification   
In the present study, TGA was bound to CS via 
amidation between the carboxylic group of 
TGA and the primary amino groups of CS. The 
reactivity of the primary amino group at the 2-
position of glucosamine subunit of chitosan is 
exploited for the immobilization of thiol 
groups. The process was performed at a pH ≤ 5 
to prevent the accidental formation of disul-
phide bonds by air oxidation during synthesis. 
The reactive thiolate anion concentration for 
the oxidation of thiol groups is low at this pH, 
which prevents the formation of disulphide 
bonds. Ellman’s reagent was employed in the 
determination of the amount of reduced and 
oxidized thiol groups immobilized (Hornof et 
al., 2003) without previous quantitative reduc-
tion of disulfide bonds with borohydride. The 
CS-TGA conjugate exhibited 236 ± 26 µmol 
thiol groups per gram of polymer. A degree of 
modification of 25–250 mmol thiol groups per 
gram of chitosan leads to the highest improve-
ment in the mucoadhesive and permeation en-
hancing properties of these thiolated chitosans 
(Sreenivas and Pai, 2009).  
 
Gel formulation and freeze-drying 
Flexible, tough, non-brittle and porous freeze-
dried annealed and non-annealed CS-TGA-
BSA wafers were produced with medium mo-
lecular weight chitosan as the base matrix. The 
primary drying phase of the freeze-drying cycle 
was deemed complete when the product tem-
perature measured by means of probes equalled 
the shelf temperature of -30 °C after 14 hours. 
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Annealing as a process step maintains samples 
at a specified temperature below the equilib-
rium freezing point but above the glass transi-
tion temperature. The incorporation of an an-
nealing process helps to achieve faster water 
vapour transport, shorter primary drying time 
and elegant porous wafers (Searles t al., 
2001b). This allows for the formation of larger 
ice crystals resulting in increased sublimation 
rate during the primary drying stage, creating 
larger pores in the process. In addition, the 
process of annealing facilitates crystallisation 
of active ingredients and the cryoprotectant 
(mannitol). This promotes solute and ice crystal 
growth and prevents premature crystallisation 
of metastable glass such as D-mannitol.  
 
Physico-mechanical characterisation of 
wafers 
SEM 
SEM was used to study the pore size and struc-
ture of the freeze-dried wafers (morphology).  
Figure 1 shows representative micrographs of 
the freeze-dried wafers. The micrographs from 
the SEM show the effect of annealing on the 
pore size. Annealing promotes the merging of 
smaller ice crystals to form larger ones, the 
sublimation of which creates larger pores. The 
wafers formed an interconnecting network of 
polymeric circular pores, with comparable pore 
size distribution.  The annealed CS-TGA-BSA 
wafers however, formed more fibrous spongy- 
like porous network.  
 
Swelling capacity 
The difference in the swelling capacities of the 
annealed and the non-annealed CS-TGA-BSA 
wafers (Table 1) was statistically significant (p 
< 0.003). It is worth noting that the annealed 
wafers maintained their structural integrity dur-
ing the incubation period (4 hours) due to the 
stronger mechanical structure. This was not the 
case for the non-annealed wafers which formed 
loose jelly-like and rather unstable swollen 
structures that consequently disintegrated upon 
removal from the hydration medium after two 
(2) hours of incubation at 37 °C. 
 
Moisture content 
The residual moisture contents of the freeze-
dried wafers are shown in Table 1. The an-
nealed wafers had a slightly lower residual 
moisture content compared to the non-annealed 
products; however, no significant statistical 
difference was observed (p > 0.3). The loss in 
weight observed for all the samples during the 
constant heating stage occurred between 60 °C 
and 120 °C, an indication of the fact that 
weight loss was due to bound water. Attaining 
adequate residual moisture content for wafers is 
vital as lower water content reduces molecular 
mobility and increases shelf-life by avoiding 
premature hydration of the active protein drug 
(Bunte et al., 2010).  
Lyophilized thiolated-chitosan wafers...  
Fig. 1: Representative SEM micrographs showing annealed and non-annealed CS-TGA-BSA 
wafers  ((a) Non-annealed CS-TGA-BSA  (b) Annealed CS-TGA-BSA)  
  
Annealed CS-TGA-BSANon-annealed CS-TGA-BSA 100 µm 100 µma b 
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Sample        % Moisture content 
        (n=4, mean + SD)  
       % swelling capacity 
         (n=4, mean + SD)  
 Annealed 
CS-TGA-BSA  
                1.7 ± 0.1                482 ± 18.2  
Non Annealed 
CS-TGA-BSA  
                1.9 ± 0.4                434.0 ± 3.1  
In vitro mucoadhesion studies  
The process of annealing led to significant dif-
ferences in the mucoadhesive properties of the 
CS-TGA wafers. The annealed CS-TGA-BSA 
wafers showed significant improvement in mu-
coadhesive properties (Fig. 2) compared to the 
non-annealed CS-TGA-BSA wafers. The an-
nealed CSTGA-BSA wafers with enhanced 
swelling capacity had higher PAF and cohe-
siveness compared to the non-annealed CS-
TGA-BSA wafers. The total work of adhesion 
(TWA) further showed a statistically significant 
difference (p < 0.0001) between the annealed 
and non annealed CS-TGA-BSA wafers, with 
an approximately 4-fold increase in mucoadhe-
sive strength. The major differences observed 
in the PAF, TWA and cohesiveness of the wa-
fers were largely due to the increased mucoad-
hesive strength impacted by the mechanically 
strong and fibrous porous structure of the an-
nealed wafers. 
 
In vitro BSA release profiles 
The dissolution profiles of BSA from the freeze
-dried wafers in 0.1M PBS is shown in Fig. 3. 
The total cumulative percent BSA release from 
the annealed and non annealed CS-TGA-BSA 
CS-BSA were 95.2 ± 7.3 % and 84.0 ± 4.7 % 
respectively. This difference is considered to be 
statistically significant (p < 0.05) with both 
formulations exhibiting sustained release pro-
files, typical of chitosan based formulations. 
The drug release may have been facilitated by 
the porous network of freeze-dried wafers as a 
result of increased surface of the dispersed drug 
in the porous cake which accelerates dissolu- 
Table 1: Percentage drug loading capacity, moisture content and hydration capacity of wa-
fers 
 
tion significantly (Bunte et al., 2010). The total 
percent release was higher from the annealed 
CSTGA than the non annealed CS-TGA wafers 
due to its higher rate of hydration and enhanced 
cohesiveness. The cohesion and stability of a 
drug delivery system over the intended duration 
of drug release is often a requirement for con-
trolled release (Peppas and Bury, 1985). The 
lower total percent release of BSA could be 
attributed to the reduced cohesiveness of the 
non-annealed wafers.  
 
Stability of protein in freeze-dried wafers 
 DSC 
Multiple glass-transitions detected by DSC 
after freeze-drying indicate possible phase 
separation of protein in the freeze-dried wafer 
and/or presence of metastable crystalline struc-
tures. For phase separation studies after freeze-
drying, no glass-transition temperatures were 
detected in the freeze-dried wafers, an indica-
tion of product stability during storage. 
 
ATR- FTIR analysis 
To further investigate the secondary structure 
of BSA in the drug loaded wafers, ATR-FTIR 
spectroscopy was employed. Structural infor-
mation was obtained for the protein loaded 
freeze-dried wafers through the analysis of the 
conformationally sensitive amide I band, which 
is located between 1600 and 1700 cm−1 (Fig. 4).  
This band is due to the in-plane C=O stretching 
vibration, weakly coupled with C-N stretching 
nd in-plane N-H bending. Each type of secon-
dary structure (i.e. α-helix, β-turn and disord-  
ered gives rise to a different C=O stretching 
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Fig. 2: In vitro  mucoadhesion force measurements of wafers showing the PAF, TWA and co-
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Fig. 3: Cumulative percent BSA release from annealed and no-annealed CS-TGA-BSA wa-
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frequency which has a characteristic band posi-
tion. The ATR-FTIR spectra show that the ab-
sorption peaks of annealed and non annealed 
CS-TGA-BSA at 1647cm−1 (amide I band) 
were stronger than those of native BSA due to 
the presence of chitosan. The absorption peak 
at 1574cm-1 is usually attributed to amide II 
band (C-N stretching and N-H bend) present in 
both BSA and chitosan. 
 
In all FT-IR patterns, the main peaks corre-
sponding to α-helical remained unchanged, 
suggesting that the protein structure maintained 
its folded conformation, and was neither de-
graded nor hydrolyzed during the production of 
freeze-dried CSTGA- BSA wafers irrespective 
of annealing process. 
 
Physical stability of BSA- CD 
The conformational stability of in vitro released 
BSA from the freeze-dried wafers was assessed 
by CD. The CD profile of native BSA and BSA 
released from the wafers, both in PBS at pH 6.8 
in far UV range are shown in Fig. 5. As is evi-
dent from this figure, the native BSA had two 
minima around 208 and 222nm; the first band 
was assigned to α-helical structure, while the 
second band was assigned to the β-structure.  
 
These results are consistent with the crystal 
structure of BSA (Quiming et al., 2005). The 
ratios between the mean residue ellipticity at 
208 and 222nm ([θ] 208/[θ]222) were 1.10, 1.11 
and 1.11 for native BSA and BSA released 
from the annealed and non annealed CSTGA-
BSA respectively. 
 
The similarity of the far-UV CD spectra and the 
mean residue ellipticity obtained confirmed the 




The various techniques used to characterise the 
freeze-dried annealed and non annealed 
thiolated chitosan wafers have indicated that 
the hydration capacity, mucoadhesion proper-
ties and release characteristics are influenced 
by the annealing process. The annealing step in 
the freeze-drying cycle helped to obtain wafers 
with the advantage of enhanced mucoadhesion 
properties, hydration capacity and consequently 
drug release property. The final freeze-dried 
product was an elegant, mechanically strong 
cake and is expected to exhibit long-term stor-
age stability as the secondary structure of BSA 
was found to be conformationally stable. The 
principal implication of these findings is the   
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potential application of the novel freeze-dried 
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